XDx's AlloMap(r) Considered 'Medically Necessary' by Aetna Inc. for Heart Transplant Recipients.
In: Biomedical Market Newsletter, 2011-03-31, S. 299-300
serialPeriodical
Zugriff:
The article reports that Aetna Inc., a provider of health insurance in the U.S., has determined the importance of XDx Inc.'s AlloMap molecular expression testing in monitoring rejection in heart transplant recipients more than one year after a heart transplant. It says that the determination contributes to the inclusion of Aetna in the growing list of insurers recognizing the clinical effectiveness of AlloMap. It also discusses the determination's impact on XDx.
Titel: |
XDx's AlloMap(r) Considered 'Medically Necessary' by Aetna Inc. for Heart Transplant Recipients.
|
---|---|
Zeitschrift: | Biomedical Market Newsletter, 2011-03-31, S. 299-300 |
Veröffentlichung: | 2011 |
Medientyp: | serialPeriodical |
ISSN: | 1064-4180 (print) |
Schlagwort: |
|
Sonstiges: |
|